Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature

被引：10

作者：

John, Alexius ^{[1
,2
]}

Spain, Lavinia ^{[2
]}

Hamid, Anis A. ^{[1
,2
,3
,4
]}

机构：

[1] Eastern Hlth, Dept Med Oncol, Melbourne, Vic 3128, Australia

[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic 3000, Australia

[3] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3128, Australia

[4] Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 01期

关键词：

non-clear cell; renal cell carcinoma; papillary; hereditary leiomyomatosis and renal cell cancer; chromophobe; medullary; collecting duct; COMPREHENSIVE MOLECULAR CHARACTERIZATION; OPEN-LABEL; PHASE-II; SUNITINIB; CABOZANTINIB; EPIDEMIOLOGY; MULTICENTER; MONOTHERAPY; EXPRESSION; CRIZOTINIB;

D O I：

10.3390/curroncol30010070

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted therapies have predominantly been conducted in patients with clear cell histology. A comprehensive review of the literature has been undertaken in order to describe molecular pathogenic mechanisms pertaining to each nccRCC subtype, and concisely summarise findings from therapeutic trials conducted in the nccRCC space.

引用

页码：923 / 937

页数：15

共 50 条

[21] Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy
Valenca, Loana B.
Hirsch, Michelle S.
Choueiri, Toni K.
Harshman, Lauren C.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (06) : 383 - 391
[22] Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
Sepe, Pierangela
Ottini, Arianna
Pircher, Chiara Carlotta
Franza, Andrea
Claps, Melanie
Guadalupi, Valentina
Verzoni, Elena
Procopio, Giuseppe
CANCERS, 2021, 13 (15)
[23] Targeted therapies and the treatment of non-clear cell renal cell carcinoma
Bellmunt, J.
Dutcher, J.
ANNALS OF ONCOLOGY, 2013, 24 (07) : 1730 - 1740
[24] Updates in the Systemic Therapy Options for Clear Cell and Non-Clear Cell Renal Cell Carcinoma
Spiess, Philippe E.
Johnstone, Peter A. S.
Jonasch, Eric
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5):
[25] A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
Osterman, Chelsea K.
Rose, Tracy L.
KIDNEY CANCER, 2020, 4 (01) : 15 - 27
[26] Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma
Inokuchi, Junichi
Goto, Shunsuke
Monji, Keisuke
Eto, Masatoshi
ANNALS OF ONCOLOGY, 2023, 34 : S1362 - S1362
[27] Renal cell carcinoma: The effect of targeted therapies on clear cell and non-clear cell histologies.
Marascio, Joseph A.
Rabatic, Bryan M.
Zaenger, David
Madden, Nicholas A.
Marchan, Edward M.
McDermott, David
Misiura, Anne Kathryn
Shaaban, Sherif
Dasher, Byron G.
Huang, Ke
Pishgou, Mahboubeh
Martin, William D.
Aletan, Maryam
Howington, Jed W.
Albasheer, Ahmad M.
Amoush, Ahmad
Stewart, John G.
Kong, Feng-Ming
Ferguson, Catherine L.
Mourad, Waleed F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[28] Morphological features and prognosis of non-clear cell renal cell carcinoma types
Zakharava, V.
Liatkouskaya, T.
Kiselev, P.
Cherstvoy, E.
Lapec, A.
VIRCHOWS ARCHIV, 2018, 473 : S335 - S336
[29] Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
Bergmann, Lothar
Weber, Sarah
Hartmann, Arndt
Ahrens, Marit
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1273 - 1286
[30] EFFICACY AND SAFETY OF SUNITINIB IN PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA
Lee, J. -L.
Ahn, J. -H.
Park, S. H.
Lim, H. Y.
Lee, S. H.
Kim, T. -M.
Cho, Y. -M.
Song, C.
Hong, J. H.
Kim, C. -S.
Ahn, H.
ANNALS OF ONCOLOGY, 2012, 23 : 141 - 141

← 1 2 3 4 5 →